Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Brain and CNS tumors
ML-guided PPRT (dose-escalated RT boost) doubles PFS in newly diagnosed IDH-wt glioblastoma—at a necrosis cost
Personalized precision radiation therapy (PPRT) is an ML-guided radiotherapy dose-escalation approach that uses MRI-derived “tumor infiltration” maps to boost dose beyond conventional fields; it was prospectively…
NCT03477513 - Trial result Spotlight
Kidney cancer
SABR (26Gy×1 or 42Gy/3fx) Delivers 100% 7-Year Local Control in Inoperable Primary RCC (FASTRACK II)
Stereotactic ablative body radiotherapy (SABR; high-dose, image-guided hypofractionated RT) was tested in FASTRACK II (TROG 15.03), a multicentre, non-randomised Phase 2 study in medically inoperable/high-risk or…
- Trial result Spotlight
Non-small cell lung cancer
CJRB-101 (live Leuconostoc mesenteroides biotherapeutic) + PD-1 blockade drives 58% ORR in PD-L1-high 1L metastatic NSCLC
CJRB-101 is an oral live biotherapeutic product (novel *Leuconostoc mesenteroides* strain) designed to remodel the gut microbiome/tumor microenvironment and was combined with pembrolizumab (anti–PD-1) in a…
NCT05877430 - Trial result Spotlight
Cervical and other gynecologic cancers
T-DXd (HER2 ADC) drives ~45–58% ORR in pretreated HER2-expressing endometrial / cervical / ovarian cancers
Trastuzumab deruxtecan (T-DXd; Enhertu) is a HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload, evaluated at 5.4mg/kg in the open-label Phase 2 DESTINY-PanTumor02 study…
NCT04482309 - New trial Spotlight
Multiple myeloma
Phase 2 Linvoseltamab BCMA×CD3 bispecific T‑cell engager vs Isa‑KRd + ASCT in high‑risk NDMM.
MMRC Horizon Two (NCT07053436) is an open-label, randomized, adaptive platform Phase 2 trial in transplant-eligible, high-risk newly diagnosed multiple myeloma with measurable, symptomatic disease. The shared control…
NCT07053436 Exploratory - New trial Spotlight
Prostate cancer
Phase 1b/2 AZD9574 PARP1 inhibitor + AZD2265 (FPI-2265) PSMA-targeted actinium-225 alpha radioconjugate in mCRPC.
AstraZeneca’s open-label, multi-center platform study in metastatic prostate cancer includes Sub-study 1 for metastatic castration-resistant prostate cancer (mCRPC), testing AZD9574 (a PARP1-selective small-molecule…
NCT07590934 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 1/2 navlimetostat PRMT5 inhibitor + pumitamig PD-L1×VEGF-A bispecific in MTAP-loss NSCLC.
This MD Anderson–sponsored Phase 1/2 study tests navlimetostat (aka MRTX1719/BMS-986504), an MTA-cooperative PRMT5 inhibitor designed to preferentially suppress PRMT5 activity in MTAP-deleted tumors, combined with…
NCT07579221 Exploratory - New trial Spotlight
Lymphoma
Phase 3 PTCL-STAT tests high-dose chemotherapy (DNA-damaging cytotoxic conditioning) + autologous stem cells
This randomized Phase 3 ECOG-ACRIN study (PTCL-STAT; EA4232) asks whether consolidative high-dose chemotherapy followed by autologous stem cell transplant (ASCT) improves outcomes versus observation alone for…
NCT06724237 Registrational - New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 rocbrutinib (LP-168) dual covalent/reversible BTK inhibitor vs pirtobrutinib non-covalent BTK inhibitor.
Newave Pharmaceutical is running this Phase 3, randomized, open-label, global multicenter trial in relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, enrolling ~306 adults and randomizing 1:1 to…
NCT07342478 Registrational - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 1 BSB-2002 mutant NPM1–targeted TCR-T therapy in relapsed/refractory AML
This Phase 1, open-label, dose-finding study evaluates BSB-2002, a personalized autologous T cell receptor–engineered T cell (TCR‑T) therapy whose introduced TCR recognizes a mutant NPM1 peptide presented by…
NCT07583303 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 RLY-8161 trial tests an NRAS-selective small-molecule inhibitor (NRAS target)
This Phase 1 first-in-human, open-label, multicenter study evaluates RLY-8161—an NRAS-selective small-molecule inhibitor—from Relay Therapeutics in adults with unresectable Stage III/IV NRAS-mutant melanoma or other…
NCT07584226 First-in-human - Trial result Spotlight
Head and neck cancer
BCA101 (EGFR/TGF‑β bifunctional antibody) + pembrolizumab drives 54% ORR in 1L HPV− R/M HNSCC
Ficerafusp alfa (BCA101) is a bifunctional EGFR-targeting antibody fused to a TGF‑β “trap,” designed to counter EGFR-driven signaling and TGF‑β–mediated immune exclusion; it was combined with pembrolizumab…
NCT04429542 - Trial result Spotlight
Head and neck cancer
Trastuzumab deruxtecan (HER2 ADC) drives 67% RECIST responses in HER2-low/HER2-mutant salivary/lacrimal cancers
Trastuzumab deruxtecan (T-DXd; DS-8201), a HER2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload, was given to patients with recurrent/metastatic secretory gland cancers of the head and…
- Trial result Spotlight
Skin cancer (non-melanoma)
ALA-PDT (20% aminolevulinic acid + blue light) Delivers 100% Histologic Clearance in Facial cSCC in situ
In the single-center, investigator-initiated, open-label NCT06159842 study, patients with biopsy-confirmed facial cutaneous squamous cell carcinoma in situ (cSCCis/Bowen disease) received 2 cycles of 20%…
NCT06159842 - Trial result Spotlight
Pancreatic cancer
Daraxonrasib (RMC-6236) RAS(ON) multiselective inhibitor delivers 35% ORR in 2L RAS G12 PDAC
Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that binds GTP-bound mutant and wild-type RAS, evaluated in the Phase 1/2 RMC-6236-001 study (NCT05379985) in previously treated RAS-mutated PDAC.…
NCT05379985 - Trial result Spotlight
Stomach and esophageal cancer
Zolbetuximab (anti-CLDN18.2 mAb) + chemo extends PFS to 20.5 months in Japanese 1L gastric/GEJ cancer
Zolbetuximab is a monoclonal antibody targeting CLDN18.2 and is combined here with platinum/fluoropyrimidine chemotherapy as first-line therapy for CLDN18.2-positive (typically defined in SPOTLIGHT/GLOW as ≥75% tumor…
NCT03504397 - New trial Spotlight
Kidney cancer
Phase 1 LNK001 dual ENPP3/CAIX AND-gated CAR T in ccRCC
MD Anderson Cancer Center is running a Phase 1, two-part (dose escalation then expansion) study testing LNK001, an autologous CAR T-cell therapy engineered as an AND-gate that requires dual recognition of ENPP3 and…
NCT07564232 First-in-human - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 1 BSB-2002 mutant NPM1–targeted TCR-T cellular therapy in R/R AML
This Phase 1, multicenter, open-label, non-randomized dose-escalation/expansion study tests BSB-2002 for adults with relapsed or refractory acute myeloid leukemia whose leukemia harbors an NPM1 mutation and who are…
NCT07566585 First-in-human - New trial Spotlight
Acute lymphoblastic leukemia
Phase 1 TSLPR-CART anti-TSLPR (CRLF2) CAR T-cell therapy in R/R B-ALL
This first-in-human Phase 1, open-label, 3+3 dose-escalation study sponsored by the National Cancer Institute (NCI) tests autologous TSLPR-CART: a patient’s own T cells engineered to express a chimeric antigen…
NCT07572136 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 8R-70CAR (CD70 CAR-T + CXCR2 “IL-8 receptor” trafficking) in brain metastases
This first-in-human Phase 1, single-center, open-label University of Florida study (IMPACT-MET) tests the safety and feasibility of ex vivo–expanded autologous T cells engineered to express a CD70-directed CAR plus…
NCT07569263 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 ODM-212 pan-TEAD (Hippo/YAP–TEAD) inhibitor combinations in solid tumors
Orion Corporation (Orion Pharma) is running this open-label, multi-cohort Phase 1/2 study to define safety, tolerability, pharmacokinetics/pharmacodynamics, and early efficacy of ODM-212, an oral small-molecule…
NCT07563738 Exploratory - Trial result Spotlight
Prostate cancer
Pembrolizumab (PD-1) + Lenvatinib (VEGFR/FGFR multikinase) posts 36% ORR in docetaxel-pretreated mCRPC (KEYNOTE-365)
Pembrolizumab is an anti–PD-1 monoclonal antibody, and lenvatinib is an oral anti-angiogenic multikinase inhibitor (VEGFR/FGFR/PDGFRα/RET/KIT); the combination was tested in KEYNOTE-365 Cohort E (Phase 1b/2) in…
NCT02861573 - Trial result Spotlight
Non-small cell lung cancer
THIO (telomere-targeting nucleoside analog) → sequential cemiplimab (PD-1) posts 16.9-mo OS signal in 3L ICI-resistant NSCLC
THIO is a first-in-class telomere-targeting agent designed to disrupt telomere integrity in telomerase-positive tumor cells and was sequenced before cemiplimab (a PD-1 antibody) in the multicenter, open-label Phase 2…
NCT05208944 - Trial result Spotlight
Lymphoma
Pirtobrutinib (non-covalent BTK inhibitor) drives 82.5% ORR in R/R Waldenström’s at ~3-year follow-up
Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor evaluated as monotherapy in the open-label, multicentre Phase 1/2 BRUIN trial (NCT03740529) in relapsed/refractory…
NCT03740529 - Trial result Spotlight
Pancreatic cancer
Intraperitoneal nivolumab (PD-1 blockade) yields 78% ascites control with minimal toxicity in GI/pancreaticobiliary cancers
Nivolumab (Opdivo), an anti–PD-1 immune checkpoint inhibitor, was administered intraperitoneally (IP) at 20 mg in 100 mL saline after paracentesis in a small, single-arm study of cytology-confirmed malignant ascites…
NCT05745233 - New trial Spotlight
Brain and CNS tumors
Phase 1 FT536 MICA/B-directed CAR-NK (MICA/MICB-targeted) for recurrent grade 4 astrocytoma
This single-center, first-in–cancer-type Phase 1, open-label, sequential dose-escalation study tests intratumoral FT536 in adults with recurrent WHO grade 4 astrocytoma (eligible regardless of IDH mutation status)…
NCT07560865 First-in-human - New trial Spotlight
Pancreatic cancer
Phase 3 atebimetinib MEK1/2 inhibitor plus modified GnP vs standard GnP in metastatic PDAC
Immuneering’s MAPKeeper 301 is a randomized, open-label Phase 3 trial testing whether adding atebimetinib—an oral small-molecule MEK1/MEK2 inhibitor targeting the MAPK pathway—to a modified schedule of gemcitabine +…
NCT07562152 Registrational - New trial Spotlight
Head and neck cancer
Phase 1/2 ficerafusp alfa EGFR×TGF-β bifunctional antibody with pembrolizumab + neoadjuvant SBRT
Washington University School of Medicine is running this open-label, sequential-assignment Phase 1/2 trial testing whether short-course neoadjuvant SBRT plus pembrolizumab (Merck’s anti–PD-1 antibody) can be safely…
NCT07552558 Exploratory - New trial Spotlight
Colorectal cancer
Phase 1 CEA-PRIT 2.0 pretargeted alpha therapy targeting CEACAM5 (CEA)
This first-in-human, open-label Phase 1 study from Roche/Genentech evaluates CEA-PRIT 2.0, a multi-step “pretargeted” radioimmunotherapy designed to deliver the alpha-emitter lead-212 to CEACAM5 (CEA)–expressing…
NCT07416552 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 D3S-003 dual-state KRAS G12D inhibitor (targets GDP- and GTP-bound KRAS)
This first-in-human, open-label Phase 1 study evaluates D3S-003 monotherapy in adults with advanced/metastatic solid tumors harboring a KRAS p.G12D mutation, focusing on safety, tolerability,…
NCT07456046 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.